Kubota T, Chiba K, Ishizaki T
Center for Molecular Biology and Cytogenetics, SRL, Inc., Hachioji City, Japan.
Clin Pharmacol Ther. 1996 Dec;60(6):661-6. doi: 10.1016/S0009-9236(96)90214-3.
To assess the genotype pattern of S-mephenytoin 4'-hydroxylation in an extended Japanese population.
One hundred eighty-six unrelated, healthy Japanese subjects were genotyped for S-mephenytoin 4'-hydroxylase (CYP2C19) according to a genotyping technique to identify the wild-type (wt) gene and two mutations, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4. Fourty-six of the 186 subjects genotyped were phenotyped with racemic mephenytoin using the conventional 8-hour urine analysis of 4'-hydroxymephenytoin.
The frequency of poor metabolizers by the genotyping analysis was 18.8% (35 of the 186 subjects), consisting of 12 homozygous for CYP2C19m1 (m1/m1), three homozygous for CYP2C19m2 (m2/m2), and 20 heterozygous for the two defects (m1/m2). Thus the allele frequencies of CYP2C19m1 and CYP2C19m2 were calculated to be 0.29 and 0.13 (107 and 46 of the total of 372 alleles), respectively. Among the 46 subjects phenotyped, seven were identified as the poor metabolizers, with a log10 urinary excretion of 4'-hydroxymephenytoin of < 0.3% of the racemic dose. These seven subjects were genotyped as the individuals with the m1/m1 (two), m1/m2 (four) or m2/m2 (one) allele combination, indicating a complete concordance between the phenotyping and genotyping tests.
The present genotyping test confirmed that the frequency of CYP2C19 mutant gene m1 is about 2.2 times greater than another mutant gene, m2, among Japanese poor metabolizers. The genotyping of CYP2C19 discriminates between the two S-mephenytoin 4'-hydroxylation phenotypes completely in the Japanese subjects.
评估日本扩展人群中S-美芬妥因4'-羟化的基因型模式。
根据基因分型技术,对186名无亲缘关系的健康日本受试者进行S-美芬妥因4'-羟化酶(CYP2C19)基因分型,以鉴定野生型(wt)基因以及外显子5中的CYP2C19m1和外显子4中的CYP2C19m2这两种突变。在186名进行基因分型的受试者中,有46名使用传统的8小时尿液分析4'-羟基美芬妥因,对外消旋美芬妥因进行了表型分析。
通过基因分型分析,代谢不良者的频率为18.8%(186名受试者中的35名),其中包括12名CYP2C19m1纯合子(m1/m1)、3名CYP2C19m2纯合子(m2/m2)以及20名两种缺陷的杂合子(m1/m2)。因此,CYP2C19m1和CYP2C19m2的等位基因频率分别计算为0.29和0.13(在总共372个等位基因中分别为107个和46个)。在46名进行表型分析的受试者中,有7名被鉴定为代谢不良者,其4'-羟基美芬妥因的尿排泄对数为外消旋剂量的<0.3%。这7名受试者的基因分型为具有m1/m1(2名)、m1/m2(4名)或m2/m2(1名)等位基因组合的个体,表明表型分析和基因分型测试完全一致。
目前的基因分型测试证实,在日本代谢不良者中,CYP2C19突变基因m1的频率比另一个突变基因m2大约高2.2倍。CYP2C19的基因分型在日本受试者中能够完全区分两种S-美芬妥因4'-羟化表型。